Crestor versus Placebo in subjects with heart failure

Study identifier:4522IL/0098

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Controlled Rosuvastatin Multinational Study in Heart Failure CORONA A Randomized, Double-Blind, Placebo Controlled Phase III Study with Rosuvastatin in Subjects with Chronic Symptomatic Systolic Heart Failure

Medical condition

heart failure

Phase

Phase 3

Healthy volunteers

Study drug

CRESTOR

Sex

All

Actual Enrollment

5013

Study type

Interventional

Age

60 Years +

Date

Study Start Date: 01 Sept 2003

Primary Completion Date: 01 Jul 2007

Study Completion Date: 01 Jul 2007

Study design

Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Prevention

Verification:

Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals

Collaborators

Inclusion and exclusion criteria

No locations available

Arms	Assigned Interventions

Documents available

https://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_6111&studyid=1572&filename=CSR-4522IL-0098-DUtch.pdf
Download
CSR-4522IL-0098-DUtch.pdf
Download
Trial Results Summaries
Available here

Contacts

Contact

AstraZeneca Information Center Telephone: 800-236-9933, (US - 8a-7p EST)

001-800-236-9933 (Outside US)

Investigators

Principal Investigator

AstraZeneca Medical Science Director

AstraZeneca